ArticleBMC urology2025
Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of intraoperative tranexamic acid in transurethral resection of the prostate: a systematic review and meta-analysis of randomised-controlled trials.International urology and nephrology · 2026Pooled it
- Impact of laser power settings on sexual and urinary outcomes in holmium laser enucleation of the prostate: a multicenter randomized controlled trial.Lasers in medical science · 2025Trial
- Risk of New-Onset Postoperative Depression After Holmium Laser Enucleation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Nationwide Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Comparison of prostatic urethral lift (PUL) versus water vapour thermal therapy (WVTT): A focus on drug-free status and unplanned admissions.BJUI compass · 2026Article
- Association of online health information exposure with disease awareness initial symptom severity in benign prostatic hyperplasia: a cross-sectional study.The Canadian journal of urology · 2026Article
- Stem Cell-Based Strategies for Fibrotic and Neurogenic Bladder Disorders: Current Evidence, Translational Challenges, and Future Directions.Current issues in molecular biology · 2026Review
- Gaps in patient-reported outcome measures integration into the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH): qualitative insights for implementation strategies.Journal of patient-reported outcomes · 2026Article
- Exploring the Gut-Prostate Axis: Microbial Signatures Linked to Prostate Volume and Bladder Function.The Prostate · 2026Article
- Prevalence of Benign Prostatic Hyperplasia and Prostate Cancer Among Men Presenting with Lower Urinary Tract Symptoms at a Tertiary Referral Hospital in Dar es Salaam, Tanzania: A Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling.Scientific reports · 2026Article
- Evaluating the Educational Quality of Benign Prostate Surgery Videos on YouTube: A Human and AI-Based Comparative Analysis.Medeniyet medical journal · 2026Article
- Community Prevalence and Predictors of Pelvic Floor-Related Symptoms in Saudi Men: Implications for Physiotherapy-Led Care.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Characterizing the academic literature on surgical management of benign prostatic hyperplasia: A bibliometric analysis.World journal of urology · 2026Article
- Effect of biofeedback electrical stimulation combined with HoLEP on surgical outcomes in patients with benign prostatic hyperplasia complicated with detrusor underactivity: a retrospective cohort study.Frontiers in surgery · 2026Article
- Resveratrol in benign prostatic hyperplasia: mechanistic insights and therapeutic perspectives.Frontiers in immunology · 2026Review
- The impact of dietary inflammation index on benign prostatic hyperplasia: insights from patient data and animal models.Frontiers in nutrition · 2026Article
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia: A Real-World Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Classifying Major Depressive Disorder Using Multimodal MRI Data: A Personalized Federated Algorithm.Brain sciences · 2025Article
- Crosstalk between mitochondrial dysfunction and benign prostatic hyperplasia: unraveling the intrinsic mechanisms.The Canadian journal of urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign prostatic hyperplasia (BPH) is a common male urological disease around the world. This study aimed to evaluate global, regional, and national burden of BPH from 1990 to 2021, and to forecast the incidence and prevalence of BPH to 2035.
methodsUsing the data and methods of the Global Burden of Disease 2021, we presented the incidence, prevalence, and disability-adjusted life-years (DALYs) of BPH from 1990 to 2021. The trends of burden over time were assessed using estimated annual percentage changes. We applied Bayesian age-period-cohort model to forecast the incidence and prevalence of BPH to 2035.
resultsIn 2021, the global number of incident cases, prevalent cases, and DALYs of BPH were 137.88, 1125.02, and 22.36 per 100,000 populations, respectively. From 1990 to 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALYs rate (ASDR) of BPH remained stable. The highest ASIR, ASPR, and ASDR were recorded in Eastern Europe in 2021. Nationally, China had the highest number of incident cases, prevalent cases, and DALYs of BPH. With the increase of socio-demographic index, the trends of ASIR, ASPR, and ASDR all exhibit an initial rise followed by a gradual decline. The global incidence and prevalence are expected to increase from 962.42 to 7878.68 per 100,000 populations in 2022 to 998.55 and 8620.60 per 100,000 populations in 2035, respectively.
conclusionsThe persistent burden of BPH continues to pose a critical public health challenge. The escalating prevalence among middle-aged and elderly populations underscores the imperative to tackle this widespread condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.